Passage Bio Inc
NASDAQ:PASG
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.5050
  • TODAY'S CHANGE (%)
    -0.0310 (-5.7836%)
  • Bid / Lots
    0.5010/ 1
  • Ask / Lots
    0.5186/ 13
  • Open / Previous Close
    0.5400 / 0.5360
  • Day Range
    0.5000
    0.5613
  • 52 Week Range
    0.4510
    1.7900
  • Volume
    400,277

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

  • Nov 13, 2024

      Show headlines and story abstract

    • 7:01AM ET on Wednesday Nov 13, 2024 by MT Newswires
      Companies Mentioned: PASG
      07:01 AM EST, 11/13/2024 (MT Newswires) -- ...

    • 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: PASG

      of new information, future developments or otherwise.
      Passage Bio, Inc. Balance Sheets (Unaudited) -------------------- ----------------- (in thousands, except share and per share data) September 30, 2024 December 31, 2023 -------------------------- -------------------- --------------------- Assets Current assets: Cash and cash equivalents $ 32,292 $ 21,709 Marketable securities 52,534 92,585 Prepaid expenses and other current assets 1,210 923 Prepaid research and development 1,180 2,742 --------------- -------------- Total current assets 87,216 117,959 Property and equipment, net 10,036 15,295 Right of use assets - operating leases 14,037 16,858 Other assets 463 433 --------------- -------------- Total assets $ 111,752 $ 150,545 =============== ============== Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,489 $ 1,298 Accrued expenses and other current liabilities 6,729 11,670 Non-refundable sublicense payments received 5,000 -- Operating lease liabilities 3,733 3,373 --------------- -------------- Total current liabilities 16,951 16,341 Operating lease liabilities - noncurrent 22,085 22,921 --------------- -------------- Total liabilities 39,036 39,262 --------------- -------------- Stockholders' equity: Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both September 30, 2024 and December 31, 2023 -- -- Common stock, $0.0001 par value: 300,000,000 shares authorized; 61,767,286 shares issued and outstanding at September 30, 2024 and 54,944,130 shares issued and outstanding at December 31, 2023 6 5 Additional paid-in capital 719,188 705,789 Accumulated other comprehensive income (loss) 32 (43) Accumulated deficit (646,510) (594,468) --------------- -------------- Total stockholders' equity 72,716 111,283 --------------- -------------- Total liabilities and stockholders' equity $ 111,752 $ 150,545 =============== ============== Passage Bio, Inc. Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, ----------------------------- ---------------------------------- (in thousands, except share and per share data) 2024 2023 2024 2023 ------------------ --------------- ------------ ----------------- --------------- Operating expenses: Research and development $ 8,656 $ 15,098 $ 30,621 $ 49,258 General and administrative 7,251 8,184 20,276 35,295 Impairment of long-lived assets 4,795 5,390 5,233 5,390 ---------- ---------- ---------- ---- ---------- Loss from operations (20,702) (28,672) (56,130) (89,943) Other income (expense), net 1,362 1,562 4,088 4,639 ---------- ---------- ---------- ---- ---------- Net loss $ (19,340) $ (27,110) $ (52,042) $ (85,304) ========== ========== ========== === ========== Per share information: Net loss per share of common stock, basic and diluted $ (0.31) $ (0.49) $ (0.87) $ (1.56) ========== ========== ========== === ========== Weighted average common shares outstanding, basic and diluted 61,763,346 54,789,410 59,920,537 54,697,967 ========== ========== ========== ==== ========== Comprehensive loss: Net loss $ (19,340) $ (27,110) $ (52,042) $ (85,304) Unrealized gain (loss) on marketable securities 99 148 75 774 ---------- ---------- ---------- ---- ---------- Comprehensive loss $ (19,241) $ (26,962) $ (51,967) $ (84,530) ========== ========== ========== === ==========

    • 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: PASG

      of new information, future developments or otherwise.
      Passage Bio, Inc. Balance Sheets (Unaudited) -------------------- ----------------- (in thousands, except share and per share data) September 30, 2024 December 31, 2023 -------------------------- -------------------- --------------------- Assets Current assets: Cash and cash equivalents $ 32,292 $ 21,709 Marketable securities 52,534 92,585 Prepaid expenses and other current assets 1,210 923 Prepaid research and development 1,180 2,742 --------------- -------------- Total current assets 87,216 117,959 Property and equipment, net 10,036 15,295 Right of use assets - operating leases 14,037 16,858 Other assets 463 433 --------------- -------------- Total assets $ 111,752 $ 150,545 =============== ============== Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,489 $ 1,298 Accrued expenses and other current liabilities 6,729 11,670 Non-refundable sublicense payments received 5,000 -- Operating lease liabilities 3,733 3,373 --------------- -------------- Total current liabilities 16,951 16,341 Operating lease liabilities - noncurrent 22,085 22,921 --------------- -------------- Total liabilities 39,036 39,262 --------------- -------------- Stockholders' equity: Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both September 30, 2024 and December 31, 2023 -- -- Common stock, $0.0001 par value: 300,000,000 shares authorized; 61,767,286 shares issued and outstanding at September 30, 2024 and 54,944,130 shares issued and outstanding at December 31, 2023 6 5 Additional paid-in capital 719,188 705,789 Accumulated other comprehensive income (loss) 32 (43) Accumulated deficit (646,510) (594,468) --------------- -------------- Total stockholders' equity 72,716 111,283 --------------- -------------- Total liabilities and stockholders' equity $ 111,752 $ 150,545 =============== ============== Passage Bio, Inc. Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, ----------------------------- ---------------------------------- (in thousands, except share and per share data) 2024 2023 2024 2023 ------------------ --------------- ------------ ----------------- --------------- Operating expenses: Research and development $ 8,656 $ 15,098 $ 30,621 $ 49,258 General and administrative 7,251 8,184 20,276 35,295 Impairment of long-lived assets 4,795 5,390 5,233 5,390 ---------- ---------- ---------- ---- ---------- Loss from operations (20,702) (28,672) (56,130) (89,943) Other income (expense), net 1,362 1,562 4,088 4,639 ---------- ---------- ---------- ---- ---------- Net loss $ (19,340) $ (27,110) $ (52,042) $ (85,304) ========== ========== ========== === ========== Per share information: Net loss per share of common stock, basic and diluted $ (0.31) $ (0.49) $ (0.87) $ (1.56) ========== ========== ========== === ========== Weighted average common shares outstanding, basic and diluted 61,763,346 54,789,410 59,920,537 54,697,967 ========== ========== ========== ==== ========== Comprehensive loss: Net loss $ (19,340) $ (27,110) $ (52,042) $ (85,304) Unrealized gain (loss) on marketable securities 99 148 75 774 ---------- ---------- ---------- ---- ---------- Comprehensive loss $ (19,241) $ (26,962) $ (51,967) $ (84,530) ========== ========== ========== === ==========

Peers Headlines